MedTrace Logo

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

NCT02807844 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2021-08-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.

Conditions

Interventions

DRUG

MCS110

MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

DRUG

PDR001

MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-29
Primary Completion
2020-06-04
Completion
2020-06-04
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Finland
  • France
  • Germany
  • Hong Kong
  • Italy
  • Japan
  • South Korea
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02807844 on ClinicalTrials.gov